PDF(Pubmed)
Abstract：
BACKGROUND: Vaccination strongly reduces the risk of hospitalization and death due to coronavirus disease 2019 (COVID-19). However, the severity of the acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and the degree of protection exerted over time by vaccination remains to be fully elucidated among hospitalized comorbid and vulnerable patients with SARS-CoV-2 infection.
METHODS: We report a case series of nine hospitalized vulnerable patients who developed a SARS-CoV-2 infection during a cardiac rehabilitation inpatient program.
RESULTS: Age ranged from 50 to 81 years. All but one patient had received at least three doses of anti-COVID-19 vaccine more than 4 months before the cardiac event. Indications for cardiac rehabilitation included acute coronary syndromes, congestive heart failure, heart valve surgery, and coronary artery bypass graft. After the confirmed diagnosis of SARS-CoV-2 infection, all patients developed symptoms. Eight patients developed at least one SARS-CoV-2-related complication, including a significant increase in high-sensitivity troponin I levels, new-onset hypoxemia, persistent atrial fibrillation, non-sustained ventricular tachycardia and recurrent sinus arrest, pericardial effusion, and a persistent increase in blood pressure.
CONCLUSIONS: Almost all patients developed complications which, however, did not evolve towards more severe expressions of the disease. These data suggest that even in this new phase of the pandemic, vaccination may exert a potential role to reduce the risk of progression towards more severe disease of SARS-CoV-2 infection in vulnerable patients with cardiovascular comorbidities.
METHODS: We report a case series of nine hospitalized vulnerable patients who developed a SARS-CoV-2 infection during a cardiac rehabilitation inpatient program.
RESULTS: Age ranged from 50 to 81 years. All but one patient had received at least three doses of anti-COVID-19 vaccine more than 4 months before the cardiac event. Indications for cardiac rehabilitation included acute coronary syndromes, congestive heart failure, heart valve surgery, and coronary artery bypass graft. After the confirmed diagnosis of SARS-CoV-2 infection, all patients developed symptoms. Eight patients developed at least one SARS-CoV-2-related complication, including a significant increase in high-sensitivity troponin I levels, new-onset hypoxemia, persistent atrial fibrillation, non-sustained ventricular tachycardia and recurrent sinus arrest, pericardial effusion, and a persistent increase in blood pressure.
CONCLUSIONS: Almost all patients developed complications which, however, did not evolve towards more severe expressions of the disease. These data suggest that even in this new phase of the pandemic, vaccination may exert a potential role to reduce the risk of progression towards more severe disease of SARS-CoV-2 infection in vulnerable patients with cardiovascular comorbidities.
摘要：
背景：疫苗接种大大降低了2019年冠状病毒病（COVID-19）导致住院和死亡的风险。然而,急性呼吸综合征冠状病毒-2(SARS-CoV-2)感染的严重程度以及疫苗接种对SARS-CoV-2感染的住院合并症和易感患者的保护程度仍有待完全阐明.
方法：我们报告了9例住院易感患者在心脏康复住院计划中发生SARS-CoV-2感染的病例。
结果：年龄范围为50至81岁。除一名患者外，所有患者在心脏事件发生前4个月以上都接受了至少三剂抗COVID-19疫苗。心脏康复的适应症包括急性冠状动脉综合征，充血性心力衰竭,心脏瓣膜手术,和冠状动脉搭桥术.确诊SARS-CoV-2感染后,所有患者均出现症状。八名患者至少出现了一种SARS-CoV-2相关并发症，包括高敏肌钙蛋白I水平的显著升高,新发低氧血症,持续性心房颤动,非持续性室性心动过速和复发性窦性停搏，心包积液,血压持续升高.
结论：几乎所有患者都出现并发症，然而,并没有演变成更严重的疾病表现。这些数据表明，即使在大流行的新阶段，在有心血管合并症的易感患者中,疫苗接种可能在降低SARS-CoV-2感染向更严重疾病进展的风险方面发挥潜在作用.
方法：我们报告了9例住院易感患者在心脏康复住院计划中发生SARS-CoV-2感染的病例。
结果：年龄范围为50至81岁。除一名患者外，所有患者在心脏事件发生前4个月以上都接受了至少三剂抗COVID-19疫苗。心脏康复的适应症包括急性冠状动脉综合征，充血性心力衰竭,心脏瓣膜手术,和冠状动脉搭桥术.确诊SARS-CoV-2感染后,所有患者均出现症状。八名患者至少出现了一种SARS-CoV-2相关并发症，包括高敏肌钙蛋白I水平的显著升高,新发低氧血症,持续性心房颤动,非持续性室性心动过速和复发性窦性停搏，心包积液,血压持续升高.
结论：几乎所有患者都出现并发症，然而,并没有演变成更严重的疾病表现。这些数据表明，即使在大流行的新阶段，在有心血管合并症的易感患者中,疫苗接种可能在降低SARS-CoV-2感染向更严重疾病进展的风险方面发挥潜在作用.
